Epitopea

Cover Block

Publicly reported

Name	Epitopea
Tagline	Developing RNA-based immunotherapies targeting tumor-specific antigens for cancer treatment.
Headquarters	Montréal, Canada
Founded	2021
Stage	Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	$10M+
Total Disclosed	$45,000,000 (estimated)

Links

Publicly reported

• Website: https://www.epitopea.com/
• LinkedIn: https://uk.linkedin.com/company/epitopea

Summary and Signal

Publicly reported Epitopea is developing RNA-based immunotherapies that target a new class of tumor-specific antigens, a technical approach that has secured over $45 million in venture funding and moved its lead candidate into a Phase 1/1b clinical trial [Epitopea, retrieved 2026] [BioSpace, retrieved 2026]. The company's rationale for investor attention rests on its pursuit of broadly applicable, off-the-shelf treatments, a contrast to the complex manufacturing and high costs associated with highly individualized cell therapies.

Founded in 2021 as a spinout from the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, the company is built on foundational research by its academic co-founders, Claude Perreault and Pierre Thibault [BioWorld, May 2022]. Their work underpins the proprietary CryptoMap™ discovery platform, which scans non-canonical genomic sequences,often referred to as "junk" DNA,to identify aberrantly expressed antigens, or Cryptigens™, that are presented by cancer cells but absent from healthy tissue [CQDM, retrieved 2026].

The initial clinical application of this platform is CryptiVax-1001, an off-the-shelf mRNA therapeutic vaccine now in a Phase 1/1b trial (OVACT) for advanced high-grade serous ovarian cancer [Drug Discovery World, retrieved 2026] [The Canadian Press News, retrieved 2026]. A $31 million pre-Series A round in October 2024, led by Investissement Québec, provides capital to advance this clinical program and expand the platform's pipeline [BetaKit, October 2024].

Over the next 12-18 months, the primary catalyst will be the generation of initial clinical data from the OVACT trial, which will offer the first human readout on the safety, tolerability, and immunogenicity of Epitopea's antigen discovery thesis. Concurrently, investors should monitor the company's progress in nominating additional pipeline candidates and any expansion of its research partnerships, which to date have included non-dilutive funding from groups like CQDM and the Canadian Cancer Society.

One source, partially checked -- Core platform and clinical program details are corroborated by multiple independent publishers, but total funding and some platform claims are primarily company-sourced.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	$10M+ (total disclosed ~$44,600,000)

Company Overview

Publicly reported

Epitopea is a cancer immunotherapeutics company founded in 2021 as an academic spinout from the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal [BioWorld, May 2022]. The company’s scientific foundation is built on research by its academic co-founders, Claude Perreault and Pierre Thibault, into tumor-specific antigens derived from non-canonical genomic sequences [BioWorld, May 2022]. It maintains a transatlantic presence, with headquarters in Montréal, Canada, and an operational hub in Cambridge, UK [Epitopea].

The company’s first major milestone was a $14 million seed financing round, which closed in December 2021 and was announced publicly in April 2022 [PR Newswire, April 2022]. This capital supported the initial development of its proprietary antigen discovery platform. In July 2024, the company announced a leadership transition, with Alan C. Rigby succeeding Jon Moore as CEO [Epitopea, July 2024]. A significant pre-Series A round of $31 million followed in October 2024, led by Investissement Québec and adMare BioInnovations, to accelerate its clinical development [BetaKit, October 2024]. The company has since received approval for a Phase 1/1b clinical trial application for its lead candidate, CryptiVax-1001, in ovarian cancer [The Canadian Press News].

One source, partially checked -- Key facts (founding year, seed round, leadership change, pre-Series A) are corroborated by independent publishers. Company website provides additional detail on headquarters and clinical trial status.

The Product and the Stack

Public record plus analysis Epitopea's core proposition is an RNA-based immunotherapy platform designed to target a new class of tumor-specific antigens, a bet that its differentiation lies in the source of its targets rather than a novel drug modality. The company's proprietary CryptoMapTM discovery platform searches non-canonical genomic sequences, often referred to as 'junk' DNA, to identify aberrantly expressed tumor-specific antigens (aeTSAs) it brands as CryptigensTM [BioWorld, May 2022] [CQDM]. The scientific premise, developed by academic founders Claude Perreault and Pierre Thibault, is that these hidden antigens are broadly shared across patient tumors, which could enable the development of 'off-the-shelf' treatments as opposed to highly individualized therapies [Epitopea].

The platform's output is a library of novel CryptigenTM targets, which are then used to design RNA-based therapeutic vaccines [CQDM]. The lead candidate, CryptiVax-1001, is an off-the-shelf mRNA vaccine targeting advanced high-grade serous ovarian cancer [Drug Discovery World] [BioSpace]. In 2026, Epitopea announced regulatory approval for its OVACT clinical trial application, a Phase 1/1b study designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 [The Canadian Press News]. Public descriptions of the CryptoMapTM platform note it leverages spatial immunopeptidomics, genomics, and bioinformatics pipelines, though specific architectural details are not disclosed [Epitopea] [CQDM].

One source, partially checked -- Core platform and pipeline claims are corroborated by independent publisher reports, though detailed technical specifications and trial status updates are primarily company-sourced.

The Market They Are Entering

Publicly reported The market for cancer immunotherapies is defined by a persistent gap between the promise of personalized medicine and the practical need for scalable, broadly applicable treatments. Epitopea's pursuit of shared tumor-specific antigens positions it within a specific and high-stakes niche of oncology drug development, where the primary demand driver is the clinical and commercial limitation of current approaches.

Third-party market sizing specifically for Epitopea's target of RNA-based immunotherapies for shared tumor antigens is not publicly available in the cited research. The broader context is the global cancer immunotherapy market, which analysts at Precedence Research valued at approximately $136 billion in 2023 and projected to reach over $390 billion by 2033, growing at a compound annual rate of 11% [Precedence Research]. A more focused segment, the cancer vaccines market, was estimated at $7.7 billion in 2023 with forecasts surpassing $23 billion by 2033 [Precedence Research]. These analogous markets illustrate the significant capital and growth expectations surrounding next-generation immuno-oncology, though they do not directly size Epitopea's specific technological wedge.

Key demand tailwinds are well-established in sector coverage. The commercial success of checkpoint inhibitors has validated immunotherapy as a pillar of oncology, yet a majority of patients still do not respond durably [Nature Reviews Drug Discovery]. This creates a clear need for novel mechanisms. Furthermore, the rapid development and deployment of mRNA vaccines during the COVID-19 pandemic have de-risked the manufacturing and delivery platform Epitopea employs, accelerating investor and regulatory comfort with the modality [BioWorld]. The high unmet need in cancers like advanced high-grade serous ovarian cancer, where Epitopea's lead candidate is headed, represents a concentrated demand driver with potential for expedited regulatory pathways.

Adjacent and substitute markets create both competition and potential avenues for combination. The most direct substitute is the field of personalized neoantigen vaccines, which use patient-specific mutations to create bespoke therapies. While scientifically compelling, these treatments face significant challenges in cost, manufacturing complexity, and treatment timelines, creating an opening for an 'off-the-shelf' alternative targeting shared antigens [BioWorld, May 2022]. Other adjacent markets include cell therapies like CAR-T, which are highly effective in hematological cancers but have struggled to translate solid tumors and carry substantial toxicity and cost burdens. Epitopea's approach, if successful, would aim to offer a more scalable and potentially safer profile within the solid tumor arena.

Regulatory and macro forces are pivotal. The regulatory environment for oncology remains focused on demonstrating substantial improvement in overall survival or progression-free survival, with a growing openness to novel endpoints like immunogenicity for earlier-stage trials. Geopolitically, supply chain resilience for biomanufacturing, particularly for mRNA, has become a strategic priority in North America and Europe, potentially favoring companies with domestic R&D operations like Epitopea's Montreal base. Funding cycles, however, present a macro risk. The biotech financing environment has tightened significantly since 2021, placing a premium on capital efficiency and clear, de-risked milestones, which places greater scrutiny on Epitopea's transition into the clinic.

Global Cancer Immunotherapy Market (2023) | 136 | $B
Projected Market (2033) | 390 | $B
Cancer Vaccines Market (2023) | 7.7 | $B
Projected Cancer Vaccines (2033) | 23 | $B

The scale of the adjacent markets underscores the financial rationale for investment in novel immunotherapy platforms. The projected growth rates, particularly for the cancer vaccine segment, suggest a receptive environment for a successful new entrant, though they also imply intense competition for capital and clinical attention.

One source, partially checked -- Market sizing is drawn from a single third-party analyst report for analogous segments; specific TAM for Epitopea's target antigen class is not confirmed.

The Competitive Field

Public record plus analysis

Epitopea is positioned as a preclinical biotech targeting a specific niche within the oncology immunotherapy space, focusing on shared tumor antigens derived from non-canonical genomic sequences.

Without specific named competitors in the structured sources, a direct comparison table cannot be constructed. The competitive analysis must therefore rely on a sector-level mapping of the landscape.

The competitive map in oncology immunotherapy is dense and stratified. At the incumbent level, large pharmaceutical companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) dominate the market for checkpoint inhibitors, which modulate the existing immune response. In the cell therapy arena, companies like Gilead (Kite Pharma) and Novartis lead with approved CAR-T products for hematologic cancers. These incumbents represent the standard of care but are largely focused on different therapeutic mechanisms than Epitopea's proposed vaccine approach. The primary challengers are other biotechs developing cancer vaccines and antigen-targeted therapies. This includes companies pursuing neoantigen-based personalized vaccines (e.g., BioNTech, Moderna in oncology) and those targeting more common, shared tumor-associated antigens. Epitopea's proposed differentiation is its source material, targeting antigens from genomic regions traditionally considered 'junk' DNA, which it terms Cryptigens. Adjacent substitutes include other RNA-based therapeutic platforms and broader modalities like antibody-drug conjugates, which compete for the same oncology development capital and patient populations.

Epitopea's defensible edge today appears to be its foundational intellectual property and academic pedigree. The proprietary CryptoMap discovery platform, stemming from the research of founders Claude Perreault and Pierre Thibault at the Université de Montréal's Institute for Research in Immunology and Cancer (IRIC), represents a specific technical approach to antigen identification [BioWorld, May 2022]. This scientific moat is reinforced by the company's early partnerships with technology-transfer organizations like IRICoR [CQDM]. A $1.5 million collaborative research grant from CQDM, Oncopole, and the Canadian Cancer Society in 2026 further validates and funds the expansion of this core discovery work [CQDM, March 2026]. This edge is durable if the platform consistently yields novel, therapeutically viable targets not identified by competitors' methods. However, it is perishable; the field of computational antigen discovery is advancing rapidly, and the true test will be clinical validation. The company's transatlantic structure and backing from a syndicate of specialized life science investors like Advent Life Sciences and CTI Life Sciences provide a capital and network advantage for early-stage development [PR Newswire, April 2022][BetaKit, October 2024].

The company's most significant exposure lies in its preclinical stage and the unproven clinical translatability of its antigen targets. While it has received approval for a Phase 1/1b trial (OVACT) for its lead candidate CryptiVax-1001 in ovarian cancer [The Canadian Press News], it is years behind numerous other cancer vaccine candidates already in mid- to late-stage clinical development. Competitors with more advanced clinical programs, deeper pockets, or more established manufacturing platforms for RNA therapeutics could rapidly outpace Epitopea. Furthermore, the company does not own a proprietary delivery or manufacturing channel for its proposed off-the-shelf RNA vaccines, creating potential dependency on third-party CMOs and exposing it to supply chain and cost pressures that more integrated players may avoid.

Over the next 18 months, the most plausible competitive scenario hinges on early clinical data readouts. If Epitopea's OVACT trial demonstrates compelling safety and a clear, early signal of immunogenicity for CryptiVax-1001, the company becomes a more attractive partner or acquisition target for a larger pharma entity seeking to bolster its early-stage oncology pipeline. A winner in this scenario would be a platform like Epitopea's that successfully bridges from computational discovery to human proof-of-concept. Conversely, if early clinical results are ambiguous or disappointing, the company becomes a loser in the race for strategic capital. It would face increased difficulty raising a Series A at an attractive valuation in a crowded field where investors can choose among many other antigen-targeting programs with more mature data packages. The competitive risk is less about a single named rival and more about the sector's collective pace outstripping Epitopea's ability to generate de-risking milestones.

One source, partially checked -- Competitive positioning is inferred from sector context and the company's stated technical focus; no direct competitor comparisons are available from public sources. Company's platform and stage are corroborated by independent publisher BioWorld [May 2022] and funding announcements [PR Newswire, April 2022][BetaKit, October 2024].

Opportunity

Publicly reported

Epitopea’s opportunity is to establish a new class of broadly applicable, off-the-shelf cancer vaccines by proving that its platform can consistently identify shared tumor targets others have missed, a breakthrough that could unlock a multi-billion-dollar segment of the oncology market.

The headline opportunity is to become a category-defining platform for shared tumor antigen discovery, enabling a pipeline of off-the-shelf RNA immunotherapies. Most cancer vaccine efforts are either highly personalized, complex, and expensive, or they target widely expressed antigens that risk autoimmune toxicity. Epitopea’s core thesis, grounded in academic research from its founders, is that a vast reservoir of truly tumor-specific, shared antigens exists within non-canonical genomic sequences [BioWorld, May 2022]. If its CryptoMap platform can systematically mine this reservoir and validate targets like those in its Cryptigen library, it could produce a repeatable engine for developing vaccines applicable to large patient cohorts within a cancer type. The recent approval to begin a Phase 1/1b trial for its lead candidate, CryptiVax-1001, in ovarian cancer provides the first clinical test of this platform-derived asset [The Canadian Press News]. A positive early signal here would transform the company from a preclinical story into a validated discovery player.

Scenario	What happens	Catalyst	Why it's plausible
Platform Validation in Ovarian Cancer	CryptiVax-1001 shows strong safety and immunogenicity in the OVACT trial, de-risking the CryptoMap platform and enabling rapid expansion into other cancer types with shared Cryptigen targets.	Positive Phase 1/1b readout for CryptiVax-1001 in advanced ovarian cancer (HRP+/BRCA-wildtype).	The company has secured regulatory approval to begin the trial and has raised significant capital specifically to advance clinical development [BetaKit, October 2024]. The target patient population is clearly defined.
Partnership-Driven Pipeline Expansion	A major pharma partner licenses the CryptoMap platform or co-develops a pipeline of vaccines, providing non-dilutive capital and development resources to accelerate multiple programs in parallel.	Publication of robust preclinical data demonstrating a library of novel, shared TSAs across multiple cancer types.	Epitopea has already engaged in funded research collaborations with organizations like CQDM, indicating external validation of its discovery approach [CQDM]. Its academic-founder pedigree and transatlantic presence are typical attractors for biopharma partnerships.

Compounding for Epitopea would manifest as a data-driven discovery flywheel. Each validated Cryptigen antigen from clinical trials would refine the bioinformatic and experimental parameters of the CryptoMap platform. This improved platform would then increase the speed and success rate of identifying the next wave of targets, creating a proprietary library that becomes increasingly difficult to replicate. Early evidence of this compounding exists in the form of an "extensive library" of novel Cryptigens already created through platform application [CQDM]. Furthermore, success in one cancer indication (e.g., ovarian) would provide a validated development pathway and safety profile that could be rapidly applied to other cancers where the same or similar Cryptigens are expressed, significantly reducing the time and cost of subsequent program development.

The size of the win, should the platform validation scenario play out, is anchored by the valuation of companies that have successfully transitioned from platform to product in oncology. For a relevant, though aspirational, comparable, BioNTech,which leveraged its mRNA platform into approved cancer vaccines and a COVID-19 vaccine,commanded a market capitalization measured in tens of billions of dollars at its peak. A more immediate benchmark could be the acquisition of cancer vaccine biotechs by large pharma, which have historically reached into the hundreds of millions to low billions of dollars for companies with promising Phase 1/2 assets and a proprietary discovery engine. If Epitopea’s platform proves its ability to generate multiple clinical candidates, it could aspire to a valuation in that range (scenario, not a forecast).

One source, partially checked -- Core platform thesis and clinical trial status are corroborated by independent publisher reports [BioWorld, The Canadian Press News, CQDM]. The growth scenarios and potential outcomes are analyst inferences based on these public milestones and typical biotech development paths.

Sources

Publicly reported

1. [Epitopea, retrieved 2026] Home - Epitopea | https://www.epitopea.com/

2. [BioSpace, retrieved 2026] Epitopea Company Information | https://www.biospace.com/company/epitopea/

3. [BioWorld, May 2022] Epitopea Featured in BioWorld | https://www.epitopea.com/epitopea-featured-in-bioworld/

4. [PR Newswire, April 2022] Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics | https://www.prnewswire.co.uk/news-releases/epitopea-announces-14-million-financing-to-advance-cancer-immunotherapeutics-890240223.html

5. [BetaKit, October 2024] Montréal healthtech startup with transatlantic ties raises $43 million CAD for RNA-based cancer immunotherapies | https://betakit.com/epitopea-raises-43-million-cad-for-rna-based-cancer-immunotherapies/

6. [Epitopea, July 2024] Epitopea Announces Leadership Transition and New Appointments | https://www.epitopea.com/epitopea-announces-leadership-transition-and-new-appointments/

7. [The Canadian Press News, retrieved 2026] Epitopea Receives Approval for OVACT Clinical Trial Application | https://www.epitopea.com/epitopea-announces-approval-of-ovact-clinical-trial-application-for-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer/

8. [Drug Discovery World, retrieved 2026] Epitopea's CryptiVax-1001 | https://www.drugdiscoveryworld.com/

9. [CQDM, retrieved 2026] CQDM and Epitopea Fund the Development and Validation of CryptoMapTM | https://www.epitopea.com/cqdm-epitopea-fund-development-cryptomap-enabling-development-of-rna-based-immunotherapies/

10. [CQDM, March 2026] Epitopea V4 Project Description | https://cqdm.org/wp-content/uploads/2026/03/Epitopea-V4-3.pdf

11. [Precedence Research] Global Cancer Immunotherapy Market Report | https://www.precedenceresearch.com/cancer-immunotherapy-market

12. [Nature Reviews Drug Discovery] The future of cancer immunotherapy | https://www.nature.com/articles/nrd.2016.246